Baseline chromogranin A and its dynamics are prognostic markers in gastroenteropancreatic neuroendocrine tumors

This study assessed whether absolute chromogranin A (CgA) values at various stages of treatment have prognostic value in patients with pancreatic and midgut neuroendocrine tumors, subjected to peptide receptor radionuclide therapy with Y-[DOTA , D-Phe , Tyr ]-octreotate. CgA was determined before pe...

Full description

Saved in:
Bibliographic Details
Published in:Future oncology (London, England) England), 2017-05, Vol.13 (12), p.1069-1079
Main Authors: Rogowski, Wojciech, Wachu a, Ewa, Lewczuk, Anna, Kolesi ska- wik a, Agnieszka, I ycka- wieszewska, Ewa, Sul yc-Bielicka, Violetta, wik a, Jaros aw B
Format: Article
Language:English
Subjects:
Biomarkers
Biomarkers, Tumor
Cancer therapies
Chemotherapy
chromogranin A
Chromogranin A - blood
Clinical medicine
Cluster analysis
Combined Modality Therapy
Disease
Disease Progression
Female
Humans
Intestinal Neoplasms - blood
Intestinal Neoplasms - diagnosis
Intestinal Neoplasms - mortality
Intestinal Neoplasms - therapy
Male
Medical prognosis
Metastasis
Middle Aged
Neoplasm Grading
Neoplasm Metastasis
Neoplasm Staging
Neuroendocrine tumors
Neuroendocrine Tumors - blood
Neuroendocrine Tumors - diagnosis
Neuroendocrine Tumors - mortality
Neuroendocrine Tumors - therapy
Pancreatic Neoplasms - blood
Pancreatic Neoplasms - diagnosis
Pancreatic Neoplasms - mortality
Pancreatic Neoplasms - therapy
Peptides
Prognosis
Radiation therapy
radionuclide therapy
Stomach Neoplasms - blood
Stomach Neoplasms - diagnosis
Stomach Neoplasms - mortality
Stomach Neoplasms - therapy
Studies
survival
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study assessed whether absolute chromogranin A (CgA) values at various stages of treatment have prognostic value in patients with pancreatic and midgut neuroendocrine tumors, subjected to peptide receptor radionuclide therapy with Y-[DOTA , D-Phe , Tyr ]-octreotate. CgA was determined before peptide receptor radionuclide therapy, 6 weeks, 6, 12, 18 and 24 months after the last dose of Y-[DOTA , D-Phe , Tyr ]-octreotate. The primary end point was overall survival. Elevated baseline CgA concentrations and their relative increase within the first year of observation were unfavorable predictors of overall survival, but not progression. Even a single baseline measurement of CgA can be useful in establishing prognosis in this group, if this parameter exceeds its upper normal limit more than tenfold.
ISSN:1479-6694
1744-8301
DOI:10.2217/fon-2016-0455